TP53 and small cell lung carcinoma: This strategy, referred to as synthetic lethality, was originally developed in the setting of BRCA germline mutations in ovarian cancer patients and holds particular appeal in SCLC, where defining mutations in RB1 and P53 combine with elevated tumor mutational burden from tobacco exposure to generate additional replication stress and dependence on DNA repair mechanisms [52,53].